（文章来源：证券日报） 证券日报网讯 12月8日，乐心医疗在互动平台回答投资者提问时表示，公司拥有多维度体征健康监测产 品线，包括主营产品：智能电子血压计、电子健康秤、智能血糖监测产品、脂肪测量仪、心电监测设备 以及手环手表等，前述产品为公司主要收入来源；近年推出的产品OTC助听器和十二导联智能心电衣 （通过参股公司布局）正逐步实现商业落地（其未来对公司业绩的影响公司尚无法预判，请注意投资风 险）。公司的医疗级智能戒指目前在持续筹备优化中，尚未正式发布，该产品相对现有手表手环从功能 侧而言，在血氧、睡眠、心率、运动等基本监测功能外，还提供心血管状态的监测与评估，从外形来说 更加便携精巧、佩戴舒适；（公司曾在2019年推出医疗级心电手表LifesenseHealthWatchH1，未曾发布 H2）。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 乐心医疗回复：尊敬的投资者您好！公司拥有多维度体征健康监测产品线，包括主营产品：智能电子血 压计、电子健康秤、智能血糖监测产品、脂肪测量仪、心电监测设备以及手环手表等，前述产品为公司 主要收入来源；近年推出的产品OTC助听器和十二导联智能心电衣（通过参股公司布局）正逐步实现商 业落地（其未来对公司业绩的影响公司尚无法预判，请注意投资风险）。公司的医疗级智能戒指目前在 持续筹备优化中，尚未正式发布，该产品相对现有手表手环从功能侧而言，在血氧、睡眠、心率、运动 等基本监测功能外，还提供心血管状态的监测与评估，从外形来说更加便携精巧、佩戴舒适；（公司曾 在2019年推出医疗级心电手表Lifesense Health Watch H1，未曾发布H2）；感谢您的关注，祝您投资顺 利，谢谢。 证券之星消息，乐心医疗(300562)12月08日在投资者关系平台上答复投资者关心的问题。 投资者提问：领导好，请问公司核心产品:十二导联智能心电衣（iSENSE系列）， Nova智听OTC助听 器，医疗级智 ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [4]. Core Views - The strategic transformation of the company is showing significant results, with the AI+ healthcare model expected to reshape the valuation system [2][3]. - The company has focused on high-margin medical-grade remote health monitoring devices and services, leading to improved operational efficiency and profitability [2]. - The company is well-positioned to benefit from the expansion of the chronic disease management market and the emerging AI+ healthcare sector [8]. Financial Summary - Revenue projections for 2024-2026 are estimated at 1.013 billion, 1.266 billion, and 1.585 billion yuan, respectively, with year-over-year growth rates of 14.5%, 25.0%, and 25.2% [1][8]. - The net profit attributable to the parent company is expected to reach 64 million, 105 million, and 145 million yuan for the same period, reflecting year-over-year growth rates of 85.5%, 64.6%, and 38.2% [1][8]. - The company's return on equity (ROE) is projected to improve from 5.5% in 2024 to 10.9% in 2026 [1]. Business Segments - The health equipment segment is focusing on new product launches, including blood glucose meters and hearing aids, which are expected to gain market traction [2]. - The RPM (Remote Patient Monitoring) segment has established deep collaborations with leading clients in Europe and the US, creating a closed-loop business model [2]. - The cardiovascular digital chronic disease service segment is integrating remote health monitoring devices with AI software and medical services, with initial validation in various healthcare settings [2]. Market Position and Future Outlook - The company has accumulated a substantial amount of multi-dimensional physiological data from over ten million users, laying a solid foundation for developing a vertical AI model in the cardiovascular field [3]. - The report anticipates that the company will achieve a revenue of 1.013 billion yuan in 2024, with a corresponding net profit of 0.64 billion yuan, indicating a strong growth trajectory [8].